Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors. Correlations between somatic mutations and first-line targeted therapy outcomes have not been reported on a randomize...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Eur Urol
मुख्य लेखकों: Hsieh, James J., Chen, David, Wang, Patricia I., Marker, Mahtab, Redzematovic, Almedina, Chen, Ying-Bei, Selcuklu, S. Duygu, Weinhold, Nils, Bouvier, Nancy, Huberman, Kety H., Bhanot, Umesh, Chevinsky, Michael S., Patel, Parul, Pinciroli, Patrizia, Won, Helen H., You, Daoqi, Viale, Agnes, Lee, William, Hakimi, A. Ari, Berger, Michael F., Socci, Nicholas D., Cheng, Emily H., Knox, Jennifer, Voss, Martin H., Voi, Maurizio, Motzer, Robert J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2016
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431298/
https://ncbi.nlm.nih.gov/pubmed/27751729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.10.007
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन